MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Summary

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Timeline

Start

2020-11-09

Primary completion

2025-04-11

Completion

2025-06-25

Outcome

Met primary endpoint

release “Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470” nicox.com ↗

release “The Denali phase 3 clinical trial met its primary endpoint of demonstrating non-inferiority of NCX 470 0.1% to latanoprost 0.005% at every time point.” nicox.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Latanoprost	Small molecule	0.005 %	—
Subject	NCX 470	Unknown	0.1 %	—

Indications